Peptide Receptor Radionuclide Therapy with [ 177 Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions

Peptide Receptor Radionuclide Therapy with [ 177 Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions

This review article summarizes findings published in the last years on peptide receptor radionuclide therapy in GEP NENs, as well as potential future developments and directions. Unanswered questions remain, such as the following: Which is the correct dose and individual dosimetry? Which is the plac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2022-01, Vol.14 (3), p.584
Hauptverfasser: Del Olmo-García, Maria I, Prado-Wohlwend, Stefan, Bello, Pilar, Segura, Angel, Merino-Torres, Juan F
Format: Artikel
Sprache:eng
Schlagworte:
Chelating agents
Dosimetry
Drug dosages
Hematology
Neuroendocrine tumors
Nuclear medicine
Patients
Pediatrics
Peptides
Pharmaceuticals
Radiation
Radiation therapy
Radioisotopes
Review
Statistical analysis
Tumors
Vectors (Biology)
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This review article summarizes findings published in the last years on peptide receptor radionuclide therapy in GEP NENs, as well as potential future developments and directions. Unanswered questions remain, such as the following: Which is the correct dose and individual dosimetry? Which is the place for salvage PRRT-Lu? Whicht is the role of PRRT-Lu in the pediatric population? Which is the optimal sequencing of PRRT-Lu in advanced GEP NETs? Which is the place of PRRT-Lu in G3 NENs? These, and future developments such as inclusion new radiopharmaceuticals and combination therapy with different agents, such as radiosensitizers, will be discussed.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14030584